Opinion|Videos|September 16, 2024
Oral JAK Inhibitor Use in Atopic Dermatitis: Screening and Monitoring Patients
Medical experts discuss the patient screening process for oral JAK inhibitors and identify absolute or relative contraindications.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you screen patients for whom you are considering use of an oral JAK inhibitor?
- What results would you consider absolute or relative contraindications to the use of JAK inhibitors (Samuel 2023)?
Advertisement
Related to this article
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.
New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.
Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.
In this Q&A, Raj Chovatiya, MD, PhD, discusses where zasocitinib fits in the psoriasis treatment algorithm and what high clearance rates mean for patients.
The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.
Advertisement
Advertisement
Trending on HCPLive
1
The HCPFive: Top News for Healthcare Providers from the Week of 09/13
2
FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease
3
When Innovation Builds Clinical Confidence: Evaluating Treatment Options in Hemophilia A
4
Zasocitinib NDA Acceptance: What It Means for Psoriasis Treatment
5